secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2026-09-01T13:00:28+00:00
Accession:  0001140361-26-035189
Event type: other_material
Sentiment:  neutral
Materiality: 0.05
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics posts updated corporate presentation; no new material facts disclosed
--------------------------------------------------------------------------------

- Company posted updated corporate presentation dated September 2026 on its website on September 1, 2026.
- Presentation furnished as Exhibit 99.1; exhibit body text appears truncated in filing, so no specific figures available.
- No financial results, guidance, or business developments are disclosed in the furnished exhibit text.
- Filing signed by CFO Thomas Eastling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126035189/0001140361-26-035189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126035189/ef20081441_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-035189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer